Baseline Spasticity and Neurogenic Bladder in MS
Demyelination disrupts descending and bladder-control signaling.
- 3.4: Ashworth score (severe baseline tone)
- 8/day: Urgency episodes (untreated detrusor activity)
- ~80%: MS prevalence w/ spasticity (placeholder figure)
- ~75%: MS prevalence w/ bladder sx (placeholder figure)
Corticospinal demyelination and hypertonia
Lesions disrupt inhibitory signaling, raising resting muscle tone.
Neurogenic detrusor overactivity
Disrupted bladder-control pathways trigger urgency and frequency.
Baclofen and Tizanidine — Reducing Muscle Tone
GABA-B and alpha-2 agonism dampen excitatory spinal reflexes.
- GABA-B: Baclofen mechanism (presynaptic inhibition)
- Alpha-2: Tizanidine mechanism (agonist, spinal interneurons)
- 10–80 mg: Typical dose range (baclofen, divided doses)
- Sedation: Main side effect (dose-limiting factor)
GABA-B agonism (baclofen)
Inhibits calcium influx at spinal afferents, reducing reflex excitability.
Alpha-2 agonism (tizanidine)
Suppresses excitatory interneuron output at the spinal cord level.
Anticholinergics — Calming Detrusor Overactivity
Muscarinic receptor blockade reduces involuntary bladder contractions.
- Anticholinergic: Drug class (e.g. oxybutynin)
- M3 muscarinic: Target receptor (detrusor smooth muscle)
- 5–20 mg: Typical dose range (oxybutynin, daily)
- Dry mouth: Main side effects (constipation, blurred vision)
Muscarinic receptor blockade
Blocks acetylcholine binding, relaxing detrusor smooth muscle.
Urgency and frequency reduction
Fewer involuntary contractions lower daily urgency episode counts.
Balancing Dual Symptom Control Against Side-Effect Burden
Sedation and anticholinergic effects compound as both doses rise.
- Additive: Combined burden (sedation + dry mouth risk)
- Stepwise: Titration approach (lowest effective dose)
- Ongoing: Monitoring (tone, voiding diary, alertness)
- Balance: Goal (function over full suppression)
Cumulative CNS and anticholinergic load
Both drug classes add sedative and cognitive burden together.
Individualized dose finding
Slow titration finds the smallest doses controlling both symptoms.
Dual-Symptom Control and Quality of Life
Optimized titration improves mobility, continence, and daily function.
- ~1.0: Ashworth improvement (from baseline 3.4)
- ~2/day: Urgency reduction (from baseline 8/day)
- Low: Side-effect burden (balanced dosing achieved)
- Improved: Quality of life (mobility + continence gains)
Sustained dual-symptom management
Ongoing monitoring maintains balance as MS symptoms fluctuate.
Functional and continence gains
Reduced tone and urgency together restore daily independence.